BioCentury
ARTICLE | Clinical News

Kevetrin thioureidobutyronitrile: Additional Phase I data

August 22, 2016 7:00 AM UTC

An open-label, dose-escalation, U.S. Phase I trial in about 48 patients with advanced solid tumors showed that once-weekly 10-750 mg/m 2 IV Kevetrin given for the first 3 weeks of each 4-week cycle me...